Researchers have developed a new breakthrough method for memory research by genetically modifying the LIMK1 protein and activating it with rapamycin. This innovative approach shows potential for treating memory-related neuropsychiatric disorders and advancing neurological research.
Neuroscientists from the Pontifical Catholic University of Rome's Faculty of Medicine and Surgery and the Fondazione Policlinico Universitario Agostino Gemelli IRCCS have genetically modified a molecule, the protein LIMK1, to develop an engineered protein that enhances memory.
They added a "molecular switch" that was activated by taking a drug called rapamycin.
This is the result of a study published in the journal Science Advances, in which the Pontifical Catholic University of Rome and the Fondazione Policlinico Universitario Agostino Gemelli IRCCS participated. The research was coordinated by Claudio Grassi, full professor of physiology and chair of the Department of Neuroscience.
This research, supported by the Italian Ministry of Education, Universities and Research, the American Alzheimer's Association Foundation and the Italian Ministry of Health, has great application potential to improve our understanding of memory function and contribute to the identification of innovative solutions for the treatment of neuropsychiatric diseases such as dementia.
The role of LIMK1 in memory processes
The LIMK1 protein plays a crucial role in determining neuronal structural changes, namely the formation of dendritic spines, which enhance information transmission in neural networks and are critical in learning and memory processes.
Professor Claudio Grassi, senior author of the study, explained: "Memory is a complex process involving changes in synapses, the connections between neurons. In specific brain areas, such as the hippocampus, synapses are neural structures that play a crucial role in the formation of memories. This phenomenon, known as synaptic plasticity, involves changes in synaptic structure and function when neural circuits are activated, such as through sensory experiences. Professor Grassi added: "These experiences promote the activation of complex signaling pathways involving a large number of proteins. "
"Indeed, reduced expression or modification of these proteins is associated with changes in cognitive function. LIMK1 is one of them. Our research goal is to regulate the activity of this protein because it plays a key role in the maturation of dendritic spines between neurons." Professor Grassi emphasized: "Controlling LIMK1 with drugs means being able to promote synaptic plasticity and thus physiological processes that depend on synaptic plasticity."
Chemical genetic strategies: new ways to enhance memory
Cristian Ripoli, first author of the study and associate professor of physiology at the Catholic University, added: "The key to this innovative 'chemical genetic' strategy combines genetics and chemistry, precisely related to the use of rapamycin, an immunosuppressive drug known to extend human lifespan and have beneficial effects on the brain in preclinical models."
Professor Ripoli emphasized: "Therefore, we modified the sequence of the LIMK1 protein and inserted a molecular switch that allowed us to activate the LIMK1 protein on command by taking rapamycin. This gene therapy was used to modify the LIMK1 protein in animals suffering from senile cognitive decline. Activating it with drugs can significantly improve their memory. This approach allows us to manipulate synaptic plasticity processes and memory under physiological and pathological conditions. Additionally, it paves the way for the development of additional 'engineered' proteins that could revolutionize research and treatment in neurology."
The next step in the research will be to verify the effectiveness of this therapy in experimental models of neurodegenerative diseases that exhibit memory deficits, such as Alzheimer's disease. Professor Grassi concluded: "Further research is needed to verify the application of this technology in humans."